Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse

Next Previous
Trial Profile

A Prospective Observational Registry of H.P. Acthar Gel for the Treatment of Multiple Sclerosis Relapse

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 May 2020 Primary endpoint, Physical subscale score of the Multiple Sclerosis Impact Scale, v.1 (MSIS-29v1), has been met as per results presented at the 72nd Annual Meeting of the American Academy of Neurology
  • 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
  • 27 Feb 2020 According to a Mallinckrodt plc media release, patients were followed for up to 24 months, and a minimum of six months at 31 U.S. sites.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top